MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013 (Xervyteg®), confirming the trend communicated in May 2026 after the Oral Explanation
MaaT Pharma plans to seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened
Second opinion upon re-examination expected during CHMP session in September 2026
Regulatory News:
